Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acorda Therapeutics

- PMLiVE

Pfizer launches antibiotic resistance surveillance website

Designed for healthcare professional use ATLAS will cover 60 countries

Pfizer expands Healthcare Hub programme for tech startups

London, Stockholm, Sydney and Toronto hubs open their doors

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

Pfizer keeps nose ahead of rivals with new Ibrance approval

FDA licenses new indication for the breast cancer treatment

- PMLiVE

Pfizer resurrects its OTC bid for Viagra in the UK

Confirms MHRA review of new pharmacist-supplied status has begun

- PMLiVE

Merck, Pfizer get first OK for checkpoint inhibitor avelumab

FDA approval for rare skin cancer drug

- PMLiVE

FDA approves Newron’s Parkinson’s disease drug Xadago

Becomes first new treatment licensed for the condition in over a decade

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

- PMLiVE

Pfizer launches new antibiotic Zavicefta in UK and Germany

Biopharmaceutical company Pfizer releases MDR antibiotic

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

Deal Watch February 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

Marketing strategy in complex environments

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links